share_log

Canadian Medical Technology Consortium Collaborates on State-of-the-Art Postoperative Patient Management Platform, Led by FluidAI

Canadian Medical Technology Consortium Collaborates on State-of-the-Art Postoperative Patient Management Platform, Led by FluidAI

加拿大医疗技术 consor联合开发最先进的术后患者管理平台,由FluidAI主导
PR Newswire ·  09/09 07:00

KITCHENER, ON, Sept. 9, 2024 /PRNewswire/ - Building on the success of the Continuous Connected Patient Care (CCPC) project, a consortium of leading Canadian medtech companies, led by FluidAI Medical in collaboration with Medtronic Canada ULC, Excelar Technologies, Providence Health Care Ventures, and the University of Waterloo, has announced the launch of the Postoperative Patient Management Platform (PPMP) project under Canada's Global Innovation Cluster for digital technologies, known as DIGITAL. This initiative aims to revolutionize postoperative care through advanced artificial intelligence (AI) and machine learning technologies.

安大略省基奇纳,2024年9月9日 /PRNewswire/-在持续互联患者护理(CCPC)项目成功的基础上,由加拿大领先医疗科技公司组成的联盟由FluidAI Medical牵头,与加拿大美敦力ULC、Excelar Technologies、普罗维登斯医疗保健风险投资公司和滑铁卢大学合作,宣布启动加拿大全球创新下的术后患者管理平台(PPMP)项目数字技术集群,即数字化集群。该计划旨在通过先进的人工智能(AI)和机器学习技术彻底改变术后护理。

Predictive analytics dashboard (CNW Group/Fluid AI Medical)
预测分析仪表板(CNW 集团/Fluid AI Medical)

Postoperative complications pose significant challenges, leading to prolonged hospital stays, increased healthcare costs, and adverse patient outcomes. Studies have found nearly 15% of surgical mortality cases are potentially preventable if caught earlier[1]. Additionally, the associated costs of additional treatments following complications due to prolonged hospital stays and readmissions are estimated to be between 1.5 to 4 times higher than for primary admissions[2, 3]. The PPMP project addresses these issues by developing a sophisticated platform that utilizes in-hospital data to create predictive models for patient risk assessment. This platform will help healthcare providers make timely and informed decisions, enhancing patient care and reducing the burden on healthcare resources.

术后并发症构成重大挑战,导致住院时间延长、医疗费用增加和患者预后不利。研究发现,如果尽早发现,将近15%的手术死亡病例是可以预防的 [1]。此外,据估计,因长期住院和再入院而导致的并发症后进行额外治疗的相关费用比初次入院的费用高1.5至4倍 [2] 3]。PPMP项目通过开发一个复杂的平台来解决这些问题,该平台利用院内数据创建用于患者风险评估的预测模型。该平台将帮助医疗保健提供者做出及时和明智的决策,加强患者护理并减轻医疗资源的负担。

The primary objectives of the PPMP project include the development of advanced predictive analytics to foresee postoperative complications such as anastomotic leaks and respiratory depression. Respiratory depression, often induced by opioids administered during and after surgery, is a significant adverse event that can result in prolonged hospital stays and increased costs—up to $23,000 USD for high-risk patients [4]. Additionally, current diagnostic techniques, such as CT scans, have limited sensitivity in detecting postoperative complications like anastomotic leaks, which often go undetected for an average of 8.5 days, posing severe risks to patient health [5]. By integrating extensive data sets from electronic health records and monitoring devices, the platform will offer actionable insights for surgeons, allowing for quicker and more precise decision-making. The commercialization strategy includes initial deployment at Providence Health Care's St. Paul's Hospital in Vancouver, with plans to expand to other hospitals, leveraging partnerships to distribute the platform across Canada, the US, and global markets.

PPMP项目的主要目标包括开发先进的预测分析,以预测吻合口渗漏和呼吸抑制等术后并发症。呼吸抑制通常由手术期间和术后服用的阿片类药物引起,是一种重大的不良事件,可导致长期住院和费用增加——高危患者最高可达23,000美元 [4]。此外,当前的诊断技术,例如Ct扫描,在检测吻合口渗漏等术后并发症方面的灵敏度有限,这些并发症通常在平均8.5天内未被发现,对患者健康构成严重风险 [5]。通过整合来自电子健康记录和监测设备的大量数据集,该平台将为外科医生提供切实可行的见解,从而做出更快、更精确的决策。商业化战略包括在温哥华的Providence Health Care的圣保罗医院进行初步部署,并计划扩展到其他医院,利用合作伙伴关系将该平台分发到加拿大、美国和全球市场。

FluidAI Medical is leading the development of predictive models and integrating the Stream Platform for remote patient monitoring. Medtronic Canada is providing vital monitoring solutions and collaborating on the development of predictive analytics. Excelar Technologies is enhancing its CareFlow platform to support broader use cases in AI-driven risk prediction. Providence Health Care Ventures is facilitating feasibility trials, validating solutions, and ensuring regulatory compliance. The data governance strategy includes the highest standards of privacy, security, ethics and consent approvals and management. The University of Waterloo is conducting user needs assessments to ensure the platform meets healthcare providers' requirements. Each consortium member brings unique expertise and resources to the project, creating a robust and comprehensive solution for postoperative patient management.

FluidAI Medical正在领导预测模型的开发,并集成了用于远程患者监测的Stream平台。加拿大美敦力正在提供重要的监测解决方案,并合作开发预测分析。Excelar Technologies正在增强其CareFlow平台,以支持人工智能驱动的风险预测中更广泛的用例。普罗维登斯医疗保健风险投资公司正在促进可行性试验、验证解决方案并确保合规性。数据治理战略包括最高的隐私、安全、道德和同意批准和管理标准。滑铁卢大学正在进行用户需求评估,以确保该平台满足医疗保健提供者的要求。每个联盟成员都为该项目带来了独特的专业知识和资源,为术后患者管理创建了强大而全面的解决方案。

By integrating AI and continuous monitoring into the PPMP project, we are developing a platform that not only facilitates earlier detection of complications but also sets a new precedent for proactive, data-driven patient care." Says Youssef Helwa, CEO at FluidAI. "FluidAI is proud to be leading the collaboration of Canadian medical technology pioneers on this project which highlights our collective commitment to innovation and excellence."

通过将人工智能和持续监测集成到PPMP项目中,我们正在开发一个平台,该平台不仅可以促进早期发现并发症,而且还为主动的、数据驱动的患者护理开创了新的先例。”FluiDAI首席执行官优素福·赫尔瓦说。“FluidAI很荣幸能够领导加拿大医疗技术先驱在这个项目上的合作,这凸显了我们对创新和卓越的集体承诺。”

Rick Sethi, Sr. Director of Research & Technology and Open Innovation at Medtronic AC&M, says, "We are excited to be collaborating with amazing partners such as DIGITAL, FluidAI and our other consortium team members to find ways to reduce length of stay of patients in hospitals. The development of our AI-based Clinical Decision Support technology will help augment patient care by supporting our clinicians."

美敦力AC&m研究与技术和开放创新高级董事里克·塞西说:“我们很高兴能与DIGITAL、FluidAI和其他联盟团队成员等出色的合作伙伴合作,寻找缩短患者住院时间的方法。我们基于人工智能的临床决策支持技术的开发将通过支持我们的临床医生来帮助加强患者护理。”

"AI will revolutionize global health care systems by providing greater access and better outcomes for Canadians and for people around the world." said Sue Paish, CEO of DIGITAL. "By uniting industry leaders, innovators, and academic partners, we're building the foundation for tomorrow's breakthroughs and ensuring Canada remains at the cutting-edge of global AI innovation. We're proud to co-invest alongside innovators like FluidAI to build relevant AI solutions that advance human health while building global commercial pathways for Canadian companies."

DIGITAL首席执行官苏·派什说:“人工智能将为加拿大人和世界各地的人们提供更多的机会和更好的结果,从而彻底改变全球医疗保健系统。”“通过团结行业领导者、创新者和学术合作伙伴,我们正在为未来的突破奠定基础,并确保加拿大保持全球人工智能创新的前沿。我们很荣幸能与FluidAI等创新者共同投资,建立相关的人工智能解决方案,促进人类健康,同时为加拿大公司建立全球商业途径。”

By enhancing patient care through early detection and intervention of postoperative complications, the platform will directly improve patient outcomes. Hospitals will benefit from more efficient patient management, reduced hospital stays, and lower readmission rates, and significant cost savings. The PPMP project is a development project and is not yet licensed by Health Canada.

通过早期发现和干预术后并发症来加强患者护理,该平台将直接改善患者的预后。医院将受益于更有效的患者管理、更少的住院时间、更低的再入院率以及显著的成本节约。PPMP项目是一个开发项目,尚未获得加拿大卫生部的许可。

About FluidAI Medical

关于 FluidAI Medical

FluidAI (formerly known as NERv Technology Inc.) is a Canadian medical technology company that uses AI to aid with the early detection of postoperative complications. From general to gastrointestinal surgeries, FluidAI's mission is to empower healthcare providers with data-driven solutions that improve patient outcomes and advance postoperative care. To learn more about FluidAI and how the company is transforming postoperative care, please visit .

FluiDAI(前身为NerV Technology Inc.)是一家加拿大医疗技术公司,它使用人工智能来帮助及早发现术后并发症。从普通手术到胃肠道手术,FluidAI的使命是为医疗保健提供者提供数据驱动的解决方案,以改善患者预后并推进术后护理。要了解有关FluidAI以及该公司如何改变术后护理的更多信息,请访问。

About Medtronic Canada ULC

关于加拿大美敦力 ULC

Proud to serve Canadian healthcare for over 50 years, Medtronic Canada ULC is headquartered in Brampton, Ontario, and is a subsidiary of Medtronic PLC. We are the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people. Our technologies and therapies address 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Visit Medtronic.ca, and follow us on X and LinkedIn.

美敦力加拿大ULC总部位于安大略省布兰普顿,是美敦力集团的子公司,自豪地为加拿大医疗服务超过50年。我们是全球领先的医疗保健技术公司,通过寻找和寻找解决方案,大胆地解决人类面临的最具挑战性的健康问题。我们的使命——减轻痛苦、恢复健康和延长寿命——将一支由90,000多名充满激情的人组成的全球团队团结在一起。我们的技术和疗法可解决 70 种健康状况,包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监护系统等。在我们多样的知识、永不满足的好奇心以及帮助所有有需要的人的愿望的推动下,我们提供创新技术,每秒、每小时、每天都在改变两个人的生活。访问 Medtronic.ca,在 X 和 领英

About DIGITAL

关于数码

DIGITAL is Canada's leader in accelerating the development and commercialization of Canadian-made digital technologies that address some of the most pressing needs across our economy and society. DIGITAL's model of collaborative innovation and co-investment advances the success of Canadian businesses through the development, adoption and commercialization of Canadian-made technologies while also growing a workforce that is skilled to fill the jobs of a growing digital economy.

DIGITAL是加拿大在加速加拿大制造的数字技术的开发和商业化方面的领导者,这些技术可以满足我们经济和社会中一些最紧迫的需求。DIGITAL的协作创新和共同投资模式通过开发、采用和商业化加拿大制造的技术,推动了加拿大企业的成功,同时还培养了一支熟练的劳动力,能够填补不断增长的数字经济中的就业岗位。

DIGITAL brings together businesses, academia, community and government agencies to solve some of industry and society's biggest challenges - better and faster than any single organization can do on its own. Through the powerful model that combines cross-sector collaboration, Canadian IP creation and results-based co-investment, we unlock the potential of Canadian industry to lead and succeed in the digital world.

DIGITAL 汇集了企业、学术界、社区和政府机构,以解决行业和社会面临的一些最大挑战,比任何单一组织单独做得更好、更快。通过将跨部门合作、加拿大知识产权创造和基于结果的共同投资相结合的强大模式,我们释放了加拿大工业在数字世界中引领和成功的潜力。

Ahead of the curve starts here. For more information, visit digitalsupercluster.ca

领先的趋势从这里开始。欲了解更多信息,请访问 digitalsupercluster.ca

About Excelar Technologies

关于 Excelar 科技

Excelar's Careflow platform, comprised of Orchestrator, Timeline, and Insights, will support the project. Orchestrator connects patient data across consortium partners' platforms, AI models, and hospital systems. Timeline offers clinicians patient timeline data visualization. Insights provides observational analytics for AI model evaluation, tuning, and governance, as well as de-identified data for clinical research and quality improvement. To learn more about Careflow, visit .

Excelar的Careflow平台由Orchestrator、Timeline和Insights组成,将为该项目提供支持。Orchestrator 通过联盟合作伙伴的平台、人工智能模型和医院系统连接患者数据。Timeline 为临床医生提供患者时间表数据可视化。Insights 为 AI 模型评估、调整和治理提供观察性分析,以及用于临床研究和质量改进的去识别数据。要了解有关 Careflow 的更多信息,请访问。

About Providence Health Care Ventures

普罗维登斯医疗保健风险投资公司简介

As an expert navigator of the Canadian health care, regulatory, and technology landscape, PHC Ventures provides indispensable support to corporate, institutional and individual innovators seeking to validate and commercialize their products and ideas. PHC Ventures offers a portal to Providence Health Care in Vancouver, Canada, a renowned provincial health organization whose lengthy innovation track record and size make it an ideal incubator to validate and scale innovations. PHC Ventures actively co-develops health solutions, forges unconventional partnerships, facilitates consulting relationships with PHC clinicians, and invests in health start-ups. For more, visit

作为加拿大医疗保健、监管和技术领域的专家领航者,PHC Ventures为寻求验证和商业化其产品和想法的企业、机构和个人创新者提供不可或缺的支持。PHC Ventures为加拿大温哥华的Providence Health Care提供了一个门户。Providence Health Care是一家著名的省级卫生组织,其悠久的创新记录和规模使其成为验证和扩大创新的理想孵化器。PHC Ventures积极共同开发健康解决方案,建立非常规合作伙伴关系,促进与PHC临床医生的咨询关系,并投资健康初创企业。欲了解更多信息,请访问

About the University of Waterloo

滑铁卢大学简介

University of Waterloo is a leading global innovation hub that drives economic and social prosperity for Canada and the world. With more than 41,000 students, we are home to the world's largest co-op education talent pipeline, to game-changing research and technology, and to an unmatched entrepreneurial culture. Together, these create partnerships and solutions to tackle today's and tomorrow's challenges. Find out more at uwaterloo.ca

滑铁卢大学是全球领先的创新中心,推动加拿大和世界的经济和社会繁荣。我们拥有超过41,000名学生,拥有世界上最大的合作教育人才管道,改变游戏规则的研究和技术,以及无与伦比的创业文化。它们共同创造了伙伴关系和解决方案,以应对当今和未来的挑战。在 uwaterloo.ca 上了解更多信息

[1] "Potentially preventable deaths in the Victorian Audit of Surgical Mortality",


[2] "Hospital Costs Following Surgical Complications: A Value-driven Outcomes Analysis of Cost Savings Due to Complication Prevention",


[3] "Hospital costs associated with surgical complications: a report from the private-sector National Surgical Quality Improvement Program",


[4] "Opioid-induced respiratory depression increases hospital costs and length of stay in patients recovering on the general care floor",


[5] "Diagnosis, treatment, and consequences of anastomotic leakage in colorectal surgery," International",

[1] “维多利亚州手术死亡率审计中可能可预防的死亡”,


[2] “手术并发症后的住院费用:以价值为导向的并发症预防所节省成本的结果分析”,


[3] “与手术并发症相关的住院费用:私营部门国家手术质量改善计划的报告”,


[4] “阿片类药物诱发的呼吸抑制增加了在普通护理层康复的患者的住院费用和住院时间”,


[5] “结直肠外科吻合口渗漏的诊断、治疗和后果”,国际”,

SOURCE Fluid AI Medical

来源 Fluid AI 医疗

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发